Use of Apheretic Technologies in Cardiovascular Disease
NCT ID: NCT02380534
Last Updated: 2022-05-26
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
WITHDRAWN
NA
INTERVENTIONAL
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Adipose Tissue Inflammation in HFpEF
NCT04886713
Relationship Between Level of Hemoglobin A1c and Platelet Function in Patients Undergoing Cardiac Surgery
NCT02711124
Observational Study With Additional Procedures: Metabolomic and Ultrastructural Findings of Allograft in Heart Transplantation and Their Correlation With Graft Dysfunction.
NCT07125703
Understanding "Heparin Resistance" in Cardiac Surgery
NCT01598883
CTO-PCI in Heart Failure Patients
NCT05632653
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
active procedure
High cardiovascular risk patients will undergo H.E.L.P. apheresis.
H.E.L.P. apheresis
High cardiovascular risk patients will undergo H.E.L.P. apheresis procedure every 3 weeks for 1 year.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
H.E.L.P. apheresis
High cardiovascular risk patients will undergo H.E.L.P. apheresis procedure every 3 weeks for 1 year.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* hepatic failure
* renal failure
18 Years
70 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Fondazione IRCCS Policlinico San Matteo di Pavia
OTHER
University of Pavia
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Giuseppe Derosa
MD, PhD
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
IRCCS Policlinico S. Matteo
Pavia, , Italy
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
P-20140023880
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.